Business
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
FEATURED STORIES
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The proceeds will be used for the companies’ growth, to help develop their platforms and advance their pipelines.
Erika Cheung testified that the data manipulation happened “frequently,” in order to make the company’s lead asset look good to investors.
The mobile app, dubbed Brisa, has been designed to help patients record their disease progression regardless of condition and treatment plans.
The company announced a Phase III cardiac drug failed to meet its primary endpoint and a significant shift in its R&D efforts that have resulted in the termination of 75% of its staff.
Sanofi is shuttering Principia’s laboratories in San Francisco after its Phase III PEGASUS trial of rilzabrutinib for pemphigus failed to meet primary or key secondary endpoints.
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Centessa Pharmaceuticals and genomics testing firm Sophia Genetics have both announced plans to expand their real estate footprints in Boston.
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
South San Francisco-based Walking Fish started the week off strong by announcing its closing of a $50 million Series A financing round on Monday.